AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
1. ABBV will report Q4 2024 results on Jan. 31, 2025. 2. Analysts project EPS of $2.10 and sales of $14.83 billion. 3. Goldman Sachs remains bullish on ABBV despite past failed trials. 4. Impairment charge of $3.5 billion impacts financial forecasting. 5. Strong growth expected in core immunology offerings through 2027.